elevated systolic blood pressure (150-220 mm Hg) were included in the study. Interventions: Patients were assigned to receive intensive (target systolic blood pressure, < 140 mm Hg within 1 hr) or guidelinerecommended (target systolic blood pressure, < 180 mm Hg) blood pressure-lowering therapy. Measurements and Main Results: Presentation hyponatremia was defined as serum sodium less than 135 mEq/L. The primary outcome was death at 90 days. Multivariable logistic regression was used to assess the association of hyponatremia with important clinical events. Of 3,002 patients with available data, 349 (12%) had hyponatremia. Hyponatremia was associated with death (18% vs 11%; multivariable-adjusted odds ratio, 1.81; 95% CI, 1.28-2.57; p < 0.001) and larger baseline intracerebral hemorrhage volume (multivariable adjusted, p = 0.046) but not with baseline perihematomal edema volume nor with growth of intracerebral hemorrhage or perihematomal edema during the initial 24 hours. Conclusions: Hyponatremia at presentation is associated with increased mortality in patients with predominantly deep and modest volume intracerebral hemorrhage through mechanisms that seem independent of growth in intracerebral hemorrhage or perihematomal edema. (Crit Care Med 2016; 44:1388-1394) Key Words: hyponatremia; intracerebral hemorrhage; mortality; outcome; sodium; stroke A cute spontaneous intracerebral hemorrhage (ICH) accounts for approximately 10-25% of all strokes (1, 2) , affecting several million people worldwide each year (3) . ICH is a critical illness with up to one third of patients requiring mechanical ventilation and ICU management (4) (5) (6) . Factors predictive of poor clinical outcome include increasing age, clinical severity defined by the Glasgow Coma Scale (GCS), initial volume and extent of growth in ICH volume, intraventricular extension, and infratentorial location of ICH (7) (8) (9) (10) .
Hyponatremia is a consistent predictor of adverse outcomes not only in general medical and critically ill patients (11) (12) (13) (14) but also in those with acute ischemic stroke (15, 16) . A possible explanatory mechanism for the association in patients with stroke is fluid shift in intracranial tissue leading to cerebral edema, seizures, and delayed cerebral ischemia (17) . However, there is a paucity of data pertaining to the significance of hyponatremia specifically in patients with ICH; only one single-center retrospective study indicates hyponatremia as an independent predictor of in-hospital mortality (18) . There are no data available on whether perihematomal edema (PHE) in ICH is related to hyponatremia.
The objective of this study was to determine the prognostic significance of hyponatremia at presentation, according to clinical and imaging outcomes in a pooling analysis of ICH patients who participated in the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT 1 and 2) studies. INTERACT 1 and INTERACT 2 were international, multicenter, open, blinded endpoint assessed, randomized controlled trials; the details of which are described elsewhere (19) (20) (21) . In brief, 3,243 participants (404 from INTERACT 1 and 2,839 from INTERACT 2) with spontaneous ICH within 6 hours of onset and elevated systolic blood pressure (SBP, 150-220 mm Hg) were randomly assigned to receive intensive (target BP, < 140 mm Hg within 1 hr) or guideline-recommended (target SBP, < 180 mm Hg) BP-lowering therapy. Patients were excluded if they had a structural cerebral cause for the ICH, assessed as having a very high likelihood of death within the next 24 hours (e.g., massive ICH with midline shift of hemisphere or deep coma at presentation defined as GCS score of [3] [4] [5] or if early surgery to evacuate the ICH was planned.
MATERIALS AND METHODS

Study Design and Participants
Written informed consent was obtained from each participant or his/her legal surrogate. The study protocol was approved by an appropriate ethics committee at each hospital site. The INTERACT studies are registered with ClinicalTrials. gov (numbers, NCT00226096 and NCT00716079).
Procedures
Demographic and clinical characteristics, including prior antihypertensive use, were recorded at the time of enrollment. The severity of the stroke was assessed using the GCS and the National Institutes of Health Stroke Scale (NIHSS) (22) at baseline. Initial local laboratory variables, including serum sodium, were taken at the presentation of patients to hospital. The use of mannitol during the first 7 days of presentation was recorded. Hyponatremia was defined according to standard criteria as sodium less than 135 mEq/L at presentation (23) .
In the CT substudies, CT scans were performed according to standardized techniques at baseline and at 24 ± 3 hours after the initial CT. A total of 1,313 participants (346 INTERACT 1 and 967 INTERACT 2) underwent a repeat CT scan at 24 hours using the same procedure as the baseline diagnostic CT scan. For each CT scan, uncompressed digital CT images were collected in Digital Imaging and Communications in Medicine format on a CD-ROM identified only with the patient's unique study number. For each study, ICH and PHE volumes were calculated independently by trained neurologists who were blind to clinical and treatment data and date and sequence of scan, using computer-assisted multislice planimetric and voxel threshold techniques (24) .
The primary causes of death, available only for INTERACT 2 participants, were divided into direct effects of the ICH and cardiovascular and noncardiovascular causes.
Outcomes
For these analyses, the primary clinical outcome was death at 90 days. Secondary clinical outcomes were death or major disability combined (defined by scores 3-6 on the modified Rankin Scale [mRS] [25] ) and separately for major disability (mRS score, 3-5) at 90 days. Outcomes in the CT substudies were baseline volumes of ICH and PHE and absolute growth www.ccmjournal.org July 2016 • Volume 44 • Number 7 over 24 hours in ICH and PHE volumes. Baseline ICH volume was assessed in all patients based on the diagnostic scan, but baseline PHE, 24-hour ICH growth, and 24-hour PHE growth were only assessed in a subgroup of consecutive patients with both baseline and 24-hour scans.
Statistical Analysis
Baseline characteristics of patients in predefined groups were summarized as mean ± sd or median (interquartile range) for continuous variables and as number (%) for categorical variables, with comparisons made using Wilcoxon signed rank test or chisquare test. Associations between hyponatremia and clinical outcomes were made using categorical logistic regression with patients without hyponatremia as the reference. Multivariable analyses for clinical outcomes in model I were adjusted for age, the presence of intraventricular extension of ICH (IVH), and baseline ICH volume; in model II, further adjustment included the variables of sex, region of enrollment, history of diabetes mellitus, prior use of diuretic or antiplatelet agents, time from onset to randomization, baseline SBP, NIHSS score (≥ 14 vs < 14), lobar location, and randomized treatment. ICH volume and PHE volume were log transformed to remove skewness for all analyses. Geometrical means of these volumes were reported with 95% CI obtained by back transformation. As a significant effect of presentation hyponatremia on mortality was observed in both crude and multivariable analyses, we investigated further the causes of death in crude and multivariable logistic regression models (available only in INTERACT 2) and performed Kaplan-Meier survival analysis. In the CT substudies, associations of hyponatremia and baseline volumes of ICH and PHE and absolute growth over 24 hours in volumes of ICH and PHE were assessed by analysis of covariance, which included the same covariates as used for the clinical outcome analyses (the details of adjusting covariates are shown in Table 3 ). Sensitivity analyses involving an alternate definition of hyponatremia (sodium < 130 mEq/L), different grades of hyponatremia severity, and the inclusion of patients with only deep and lobar hemorrhages were also conducted to assess associations with the primary trial study outcome of death and major disability. Finally, we investigated the association of presentation hypernatremia (sodium > 145 mEq/L) on the 90-day clinical outcomes. Data are reported with odds ratios (ORs) and 95% CIs. A p value of less than 0.05 was regarded as indicative of statistical significance. All analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC).
RESULTS
Among 3,243 participants in the INTERACT pooled cohort, 3,002 (93%) had information on sodium levels at presentation and 90-day outcomes for inclusion in these analyses ( Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/CCM/ B660). A total of 349 patients (12%) had hyponatremia at presentation (mean sodium, 132 ± 3 mEq/L [compared with 140 ± 3 mEq/L in other patients; p < 0.001]). Table 1 shows that hyponatremic patients were more likely to have been taking a diuretic, had higher diastolic BP, larger baseline ICH volume, and more IVH, and more likely to have received mannitol within 7 days. However, there was no significant difference between the two groups in regard to clinical severity (i.e., NIHSS score), time from symptom onset to randomization, or the location of the underlying ICH.
At the 90-day outcome assessment, 64 patients (18%) with hyponatremia had died when compared with 289 patients (11%) without hyponatremia. Hyponatremic patients had a higher risk of death after multivariable adjustment (OR, 1.81; 95% CI, 1.28-2.57; Table 2 and Fig. 1) and Kaplan-Meier curves (log rank, p < 0.001; Fig. 2) . Significant associations were also found between the presentation hyponatremia and the secondary clinical outcome of death or major disability in crude analyses (OR, 1.37; 95% CI, 1.09-1.71; Table 2 ) although this was no longer significant after adjustment for covariates (OR, 1.18; 95% CI, 0.89-1.56; Table 2 and Fig. 1 ). There was no association between hyponatremia and major disability ( Table 2 and Fig. 1 ). Among those who died, hyponatremic patients had a shorter time to death than others (median 4 vs 7 d; p = 0.028; Fig. 2 ). There were no differences regarding the causes of death between the two groups in INTERACT 2 patients (Table S1, Supplemental Digital Content 2, http://links.lww.com/CCM/B661). Similar results were found in sensitivity analyses using an alternate definition of presentation hyponatremia (< 130 mEq/L) and limited to patients with only supratentorial (lobar and deep) ICH for the outcomes of death and death and major disability ( Among 2,791 patients with baseline ICH volume data, we found a significant association between presentation hyponatremia and baseline ICH volume (multivariable adjusted, p = 0.046) with larger volumes for those with hyponatremia. No such association was evident for baseline PHE volume (data from 1,119 patients; Table 3 ). Among 1,313 patients with repeated CT scans at 24 hours, no significant associations were found between presentation hyponatremia ICH (n = 1,264) and PHE (n = 1,110) growth (Table 3 ).
DISCUSSION
The present pooled analysis of the two large INTERACT studies, which included over 3,000 patients with acute spontaneous ICH, has demonstrated an association between presenting hyponatremia and early death. Although there was a significant relationship between early hyponatremia and baseline ICH volume, no associations were observed for subsequent ICH growth or for PHE volumes over 24 hours.
There are multiple studies reporting an association between hyponatremia and mortality in patients with critical illness, including acute ischemic stroke (12, 15, 16, 26) . However, data are more limited for those with acute ICH despite the importance of this condition. Although results are consistent with the previous single-center retrospective study (18) , they also provide additional insights into potential mechanisms. Our analyses with a larger and broader range of patients extend previous findings by demonstrating that hyponatremic patients present with larger ICH volumes but do not have any apparent additional expansion of the initial ICH or extension of PHE as mechanisms to explain the poor prognosis. Rather, low serum sodium following presentation may reflect chronic sodium derangements or reflect the severity of ICH, thus providing an additional impact on outcome. Two recent analyses suggest that hyponatremia is not just a marker of the severity of underlying illness but has independent adverse effects (27) on physiologic functioning of multiple organ systems (28) . A population-based study of over 14,000 adults (27) has shown a five-fold increase in mortality among subjects with hyponatremia with no significant comorbidity when compared with matched normonatremic subjects, implying an inherent negative impact of a chronic hypotonic state beyond the underlying illness. Given our ability to record the level of sodium in subjects within several hours after the onset of symptoms (median time of symptom onset to randomization was 3 hr), it is unlikely because of secondary causes, such as the syndrome of inappropriate antidiuretic hormone Model II adjusted for age, sex, region of enrollment, history of diabetes mellitus, prior use of diuretic or antiplatelet agents, time from onset to randomization, baseline systolic blood pressure, the presence of intraventricular extension, log-transformed ICH volume, lobar location, randomized treatment, and the use of mannitol. Hyponatremia, < 135 mEq/L; without hyponatremia, ≥ 135 mEq/L. secretion or cerebral salt wasting, as occurs in patients with subarachnoid hemorrhage where sodium levels decline from the second to 10th day after onset (29) . Despite our expectations that hyponatremia would promote PHE, we did not find any significant difference in the volume of PHE, either at baseline or over 24 hours, between patients with and without hyponatremia. Possible explanations include imprecise PHE volume measurements, an early assessment of PHE in INTERACT (24) , and use of a single measurement of serum sodium. Therefore, we consider that the data reflect longstanding hyponatremia wherein the brain may facilitate adaptive mechanisms to normalize osmolarity, first by compensatory displacement of water from the brain into the cerebrospinal fluid and systemic circulation and later with the extrusion of electrolytes and concomitant loss of osmotically driven water from neuronal tissue (30) . Impaired water excretory properties, multiple comorbidities, and polymedication including diuretics are plausible causes of chronic hyponatremia in our population (27) .
Novel associations of hyponatremia with larger ICH volume and the presence of IVH were observed in this study. The former might be because of uncaptured baseline factors related to ultraearly ICH growth in patients with hyponatremia or reflect the pathophysiology of ICH in hyperacute stage. The higher association of IVH with hyponatremia in larger ICH has been shown elsewhere (31, 32) .
Strengths of this study include the large sample size and heterogeneous population with early rigorous prospective and systematic evaluations after the onset of acute ICH. We also recognize some limitations in that these analyses were post hoc, observational, and not prespecified, raising the potential for confounding and bias, particularly in relation to use of single measures of sodium without accounting for regression to the mean. In addition, we used a nonstandardized single measurement of serum sodium. Long-term outcomes may also be related to sodium throughout the hospital course, but we lacked data on subsequent sodium status and management (e.g., use of hypertonic saline either for hyponatremia or intracranial pressure management) of patients. In addition, limited information exists to allow an assessment of whether hyponatremia at presentation was chronic or acute (e.g., history of heart failure, liver failure, hypothyroidism, and hypertriglyceridemia) or related to particular medications, such as carbamazepine. Therefore, our study cannot address the question of whether sodium changes are a function of the pathophysiology or treatment of ICH nor of the effects of sodium control after ICH. Finally, as the INTERACT studies excluded poor prognosis patients and those with early surgical hematoma evacuation or decompression, we were unable to investigate the sodium status or outcomes in these patients. Selection bias may, therefore, limit the generalizability of the results because this analysis was based on a clinical trial population of predominantly mild to moderate sized ICH, elevated BP, enrollment from China, and with few patients on warfarin anticoagulation. In summary, our study indicates that early hyponatremia is associated with an increased risk of death in patients with mainly deep, small to medium volume, ICH. This observation may assist in risk stratification of ICH patients although it is unclear how ICH physiologically affects sodium level or how sodium level is influenced by treatment. As such, further studies are required to assess whether correction of hyponatremia provides a viable potential treatment option in ICH.
